Home » Topics » BioWorld Science

BioWorld Science
RSS

How targeted therapies are lost in translation

June 28, 2018

Rigel announces the initiation of phase I trial of R-835

June 28, 2018

Lundbeck initiates phase I study with Lu-AF-28996 for Parkinson's disease

June 28, 2018

Phase III trial of rosiptor in interstitial cystitis/bladder pain syndrome misses primary endpoint

June 27, 2018

Summit discontinues development of ezutromid based on results of PhaseOut DMD trial

June 27, 2018

ThromboGenics plans to change name to Oxurion

June 27, 2018

Servier and Galapagos initiate phase II trial with S-201086 in osteoarthritis

June 27, 2018

FDA advisory committees recommend against approval of Remoxy ER

June 27, 2018

Pivot plans IND filing to begin clinical trials with PVT-005

June 27, 2018

Aclaris initiates phase II trial of ATI-501 for alopecia totalis and alopecia universalis

June 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...